Support Line: 0800 002 9002
General Enquiries: 01223 870008
  »  Kidney Cancer News  »  Kidney Cancer UK welcomes MHRA early access to nivolumab

Kidney Cancer UK welcomes MHRA early access to nivolumab

by | Feb 12, 2016 | Kidney Cancer News, Kidney Cancer UK News

Kidney Cancer UK has welcomed the news that the Medicines Healthcare Products and Regulatory Agency (MHRA) has granted early access to nivolumab through the Early Access to Medicines Scheme (EAMS).

nivolumab will be available through EAMS as monotherapy for the treatment of adult patients with advanced renal cell carcinoma after prior therapy. The scientific opinion is based on data from a Phase III clinical trial, in which nivolumab demonstrated a significant median overall survival benefit of 5.4 months compared to standard therapy, everolimus in patients who received prior therapy.
Nick Turkentine, CEO of Kidney Cancer UK said of the announcement: “This is the news patients with advanced kidney cancer have been waiting to hear. Nivolumab is particularly exciting because it is a new type of treatment for kidney cancer, a monoclonal antibody. It works with the body to modify how the immune system reacts to cancer cells, promoting the natural destruction of kidney cancer cells which were otherwise not recognised by the immune system. Hopefully this new class of cancer drug will lead to more developments in the battle against cancer.”

<a href="" target="_self">Malcolm Packer</a>

Malcolm Packer

Malcolm is Chief Executive Officer at Kidney Cancer UK and Kidney Cancer Scotland and has worked with the charity in various capacities for over 15 years.